Anti-tau drug
| Anti-tau drug | |
|---|---|
| Drug class | |
| Class identifiers | |
| Synonyms | Tau inhibitor |
| Mechanism of action | Block or inhibit tau |
| Biological target | Tau |
| Chemical class | Monoclonal antibodies; Antisense oligonucleotides |
| Legal status | |
An anti-tau drug, or a tau inhibitor, is a drug which blocks or inhibits tau.[1][2][3][4] They include anti-tau antibodies like semorinemab, anti-tau antisense oligonucleotides like diranersen, and anti-tau vaccines.[1][2][4] Anti-tau drugs are under development for the treatment of tauopathies like Alzheimer's disease.[1][2][4]
See also
References
- 1 2 3 Panza F, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, Bortone I, Stallone R, Cirillo N, Damiani C, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Lozupone M (2023). "Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies". Expert Opin Investig Drugs. 32 (7): 625–634. doi:10.1080/13543784.2023.2233892. PMID 37405389.
- 1 2 3 Suzuki N, Hatta T, Ito M, Kusakabe KI (2024). "Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives". Chem Pharm Bull (Tokyo). 72 (7): 602–609. doi:10.1248/cpb.c24-00069. PMID 38945936.
- ↑ Courade JP, Zetterberg H, Höglinger GU, Dewachter I (December 2025). "The evolving landscape of Alzheimer's disease therapy: From Aβ to tau". Cell. 188 (26): 7337–7354. doi:10.1016/j.cell.2025.11.033. PMID 41448139.
- 1 2 3 Lozupone M, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, Bortone I, Stallone R, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Panza F (May 2023). "The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies". Expert Opin Drug Discov. 18 (5): 515–526. doi:10.1080/17460441.2023.2200245. PMID 37042028.